Literature DB >> 33280139

Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.

Chun-Han Lo1,2,3, Hamed Khalili2,3, Paul Lochhead2,3, Mingyang Song1,2,3,4, Emily W Lopes2, Kristin E Burke2, James M Richter2, Andrew T Chan2,3,5, Ashwin N Ananthakrishnan2,3.   

Abstract

BACKGROUND: Although immune-mediated diseases (IMDs) including inflammatory bowel diseases (IBDs) are known to cluster, to what extent this is due to common environmental influences is unknown. AIM: To examine the incidence of IBD in individuals with another IMD.
METHODS: We used data from the prospective Nurses' Health Study II cohort (1995-2017) to examine the effect of diagnoses of several common IMDs on subsequent risk of Crohn's disease (CD) or ulcerative colitis (UC) using Cox proportional hazards models, adjusting for detailed diet and lifestyle confounders.
RESULTS: We documented 132 cases of CD and 186 cases of UC over 2 016 163 person-years of follow-up (median age at IBD diagnosis 50 years). Compared to participants with no history of IMD, the HRs of CD for those with 1 and ≥ 2 IMDs were 2.57 (95% CI 1.77-3.74) and 2.74 (95% CI 1.36 to 5.49), respectively (Ptrend  < 0.0001). This association was only modestly attenuated by adjustment for environmental risk factors (HR 2.35 and 2.46, respectively). The risk of UC was not increased, with multivariable-adjusted HRs of 1.22 (95% CI 0.85-1.76) and 1.33 (95% CI 0.67-2.65) for those with 1 and ≥ 2 IMDs, respectively, compared to those with none (Ptrend 0.16) (Pheterogeneity comparing CD and UC 0.037). Asthma, atopic dermatitis, psoriasis and rosacea were individually associated with higher risk of CD (HR ranging from 2.15 to 3.39) but not UC.
CONCLUSIONS: Individuals with one or more IMDs are at an increased risk for CD but not UC.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 33280139      PMCID: PMC8082435          DOI: 10.1111/apt.16210

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  55 in total

1.  Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria.

Authors:  Chin Wen Png; Sara K Lindén; Kristen S Gilshenan; Erwin G Zoetendal; Chris S McSweeney; Lindsay I Sly; Michael A McGuckin; Timothy H J Florin
Journal:  Am J Gastroenterol       Date:  2010-07-20       Impact factor: 10.864

2.  Rosacea, Use of Tetracycline, and Risk of Incident Inflammatory Bowel Disease in Women.

Authors:  Wen-Qing Li; Eunyoung Cho; Hamed Khalili; Shaowei Wu; Andrew T Chan; Abrar A Qureshi
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-25       Impact factor: 11.382

3.  Measures of obesity and risk of Crohn's disease and ulcerative colitis.

Authors:  Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Leslie M Higuchi; Charles S Fuchs; James M Richter; Andrew T Chan
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

Review 4.  Role of the microbiota in immunity and inflammation.

Authors:  Yasmine Belkaid; Timothy W Hand
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

5.  Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease.

Authors:  Jose U Scher; Carles Ubeda; Alejandro Artacho; Mukundan Attur; Sandrine Isaac; Soumya M Reddy; Shoshana Marmon; Andrea Neimann; Samuel Brusca; Tejas Patel; Julia Manasson; Eric G Pamer; Dan R Littman; Steven B Abramson
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

Review 6.  Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis.

Authors:  Hannah Burke; Jo Leonardi-Bee; Ahmed Hashim; Hembadoon Pine-Abata; Yilu Chen; Derek G Cook; John R Britton; Tricia M McKeever
Journal:  Pediatrics       Date:  2012-03-19       Impact factor: 7.124

7.  Being Overweight or Obese and the Development of Asthma.

Authors:  Jason E Lang; H Timothy Bunnell; Md Jobayer Hossain; Tim Wysocki; John J Lima; Terri H Finkel; Leonard Bacharier; Amanda Dempsey; Lisa Sarzynski; Matthew Test; Christopher B Forrest
Journal:  Pediatrics       Date:  2018-12       Impact factor: 7.124

8.  An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.

Authors:  Jun Chen; Kerry Wright; John M Davis; Patricio Jeraldo; Eric V Marietta; Joseph Murray; Heidi Nelson; Eric L Matteson; Veena Taneja
Journal:  Genome Med       Date:  2016-04-21       Impact factor: 11.117

9.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Co-occurrence of Asthma and the Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Authors:  M Ellen Kuenzig; Kirles Bishay; Richard Leigh; Gilaad G Kaplan; Eric I Benchimol
Journal:  Clin Transl Gastroenterol       Date:  2018-09-24       Impact factor: 4.488

View more
  3 in total

1.  A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease.

Authors:  Elizabeth A Spencer; Michael T Dolinger; Marla C Dubinsky
Journal:  Dig Dis Sci       Date:  2022-09-05       Impact factor: 3.487

2.  Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.

Authors:  Christopher E M Griffiths; Melinda Gooderham; Jean-Frederic Colombel; Tadashi Terui; Ana P Accioly; Gaia Gallo; Danting Zhu; Andrew Blauvelt
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-27

Review 3.  siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.

Authors:  Saman Sargazi; Rabia Arshad; Reza Ghamari; Abbas Rahdar; Ali Bakhshi; Sonia Fathi Karkan; Narges Ajalli; Muhammad Bilal; Ana M Díez-Pascual
Journal:  Cell Biol Int       Date:  2022-07-13       Impact factor: 4.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.